Project T21: unleashing the potential of cannabis-based medicinal products скачать в хорошем качестве

Project T21: unleashing the potential of cannabis-based medicinal products

Anne Schlag, PhD, Drug Science, London, UK, present real-world evidence on the effectiveness of cannabis-based medicinal products (CBMPs) for neurological conditions. At the BNA conference 2023, Dr Schlag discussed the UK's first real-world data registry, Project T21, which aims to advance scientific evidence on medical cannabis and enable patient access within the UK. Project T21, launched by the charity Drug Science in 2020, has enrolled over 3,500 patients to date, with follow-up data available at 3- and 6-months. The patients enrolled have diverse characteristics, conditions, and comorbidities. The project examined changes in health and well-being, quality of life, mood, and specific conditions including chronic pain, anxiety disorders, and PTSD. Dr Schlag also discussed the adverse effects (AEs) reported during the study, noting that the majority of AEs were mild and could be resolved easily with dose adjustments. This longitudinal assessment of AEs is important to address misconceptions and concerns associated with medical cannabis. Dr Schlag emphasizes the need for further research to understand individual patient and condition-specific responses to different types of cannabis products, beyond THC and CBD cannabinoids. The ongoing analysis of Project T21 data will provide deeper insights into these complex issues, and future outcomes will be evaluated at the one-year mark. This interview took place at The BNA 2023 International Festival of Neuroscience in Brighton, UK. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.